文献速递真菌感染

免疫标志物用于侵袭性曲霉病治疗监测与结局预测

Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers.
PubMed 文献 · J Infect Dis · 2026-01-01

本研究为ECMM多中心前瞻性队列,纳入51例血液恶性肿瘤合并 probable 或 proven 侵袭性曲霉病患者,用Olink Target 96 Inflammation panel分析3周内连续血清样本。结果显示治疗早期临床改善者差异表达蛋白多上调(CCL23除外),MMP-10可预测晚期治疗反应,第2周CXCL6和第3周MMP-10低血清浓度与更高生存概率相关。

要点

  • 治疗早期临床改善者差异表达蛋白多上调,CCL23除外。
  • MMP-10可预测晚期治疗反应,改善者第2–3周表达持续较低。
  • 第2周CXCL6和第3周MMP-10低浓度与更高生存概率相关。

核心结论

  • 免疫标志物在疾病不同状态下的动态变化可能有助于预测抗真菌治疗反应。

研究设计与样本

  • ECMM多中心前瞻性队列研究,纳入51例血液恶性肿瘤合并 probable 或 proven 侵袭性曲霉病患者,3周内连续采集血清样本,使用Olink Target 96 Inflammation panel分析。

主要发现

  • 治疗早期,临床改善患者与恶化患者相比,除CCL23外所有差异表达蛋白均上调。
  • 多个蛋白与需要从一线抗真菌治疗切换至挽救治疗显著相关。
  • 晚期治疗反应方面,MMP-10为预测因子,临床改善者第2周和第3周表达持续较低。
  • 第2周CXCL6低血清浓度和第3周MMP-10低血清浓度与更高生存概率相关。

临床怎么用

  • 动态监测血清免疫标志物可能辅助判断侵袭性曲霉病抗真菌治疗反应及预测结局。

局限性

  • 研究样本量较小(51例),免疫标志物在临床实践中的实用性尚待未来研究确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive aspergillosis (IA) is a leading cause of mortality despite antifungal therapy. Current biomarkers for treatment monitoring and outcome prediction are limited, with host biomarkers showing potential in other fungal diseases but not in IA yet. METHODS: In this ECMM multicenter study, we prospectively evaluated a cohort of 51 patients with probable or proven IA with underlying hematological malignancies. Serial serum samples, collected over a 3-week period, were analyzed using the Olink Target 96 Inflammation panel. Differential expression analyses and survival analysis for outcome prediction were performed. RESULTS: Early after treatment, all differentially expressed proteins were upregulated in patients showing clinical improvement compared with those with worsening disease, with the exception of CCL23. Multiple proteins significantly correlated with the need to switch from primary to salvage antifungal therapy. For late treatment response, matrix metalloproteinase-10 (MMP-10) emerged as predictor, with consistently lower expression during clinical improvement during Weeks 2 and 3. Moreover, low-serum concentrations of CXCL6 at Week 2 and MMP-10 at Week 3 were associated with higher survival probability. CONCLUSIONS: The dynamics of immune markers across disease states may help predicting responses to antifungal treatment. Future studies should establish their usefulness in clinical practice.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pereira A, Scott J, Sarlea A, et al. Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers. J Infect Dis. 2026. PMID: 41778487. doi:10.1093/infdis/jiag140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。